The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) drugs in development market research report provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued products.

GlobalData tracks 30 drugs in development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) by 23 companies/universities/institutes. The top development phase for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) is preclinical with 11 drugs in that stage. The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline has 30 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline products market are: Kalvista Pharmaceuticals, Pharming Group and Verseon.

The key targets in the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline products market include Plasma Kallikrein (Fletcher Factor or Kininogenin or Plasma Prekallikrein or KLKB1 or EC 3.4.21.34), Plasma Protease C1 Inhibitor (C1 Esterase Inhibitor or C1 Inhibiting Factor or Serpin G1 or SERPING1), and Coagulation Factor XII (Hageman Factor or HAF or F12 or EC 3.4.21.38).

The key mechanisms of action in the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline product include Plasma Kallikrein (Fletcher Factor or Kininogenin or Plasma Prekallikrein or KLKB1 or EC 3.4.21.34) Inhibitor with 11 drugs in Phase III. The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline products include five routes of administration with the top ROA being Oral and eight key molecule types in the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline products market including Small Molecule, and Gene Therapy.

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) overview

Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing,and difficulty breathing. Treatment includes medications such as epinephrine, antihistamines, and corticosteroids.

For a complete picture of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)’s pipeline drug market, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.